EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198 · see citing works

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414 · see citing works

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis

Corey, M. L., Edwards, L. J., Levison, H., & Knowles, M. R. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70025-8 · Cited by 352 · see citing works

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Konstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D. A., Huang, X., Lubarsky, B., Rubin, J. L., Millar, S. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 287 · see citing works

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

Sawicki, G. S., McKone, E. F., Pasta, D. J., Millar, S. J., Wagener, J. S., Johnson, C. A., & Konstan, M. W. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0578oc · Cited by 236 · see citing works

Year-to-year changes in lung function in individuals with cystic fibrosis

Liou, T. G., Elkin, E. P., Pasta, D. J., Jacobs, J. R., Konstan, M. W., Morgan, W. J., & Wagener, J. S. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.04.002 · Cited by 117 · see citing works

Characterizing aggressiveness and predicting future progression of CF lung disease

Konstan, M. W., Wagener, J. S., & VanDevanter, D. R. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60006-0 · Cited by 63 · see citing works

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30510-5 · Cited by 52 · see citing works

Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID‐19 pandemic

Patel, S., Thompson, M., Slaven, J. E., Sanders, D. B., & Ren, C. L. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25250 · Cited by 41 · see citing works

170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

Griese, M., Tullis, E. D., Chilvers, M. A., Fabrizzi, B., Jain, R., Legg, J., Mall, M. A., McKone, E. F., Polineni, D., Poplawska, K., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(22)00861-x · Cited by 12 · see citing works

Cystic fibrosis

Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 223 · see citing works

CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis

Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173 · see citing works

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis

Bacalhau, M., Camargo, M., Magalhães‐Ghiotto, G. A. V., Drumond, S., Castelletti, C. H. M., & Lopes‐Pacheco, M. (2023) · Pharmaceuticals · doi:10.3390/ph16030410 · Cited by 114 · see citing works

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Hisert, K. B., Birket, S. E., Clancy, J. P., Downey, D. G., Engelhardt, J. F., Fajac, I., Gray, R. D., Lachowicz-Scroggins, M. E., Mayer-Hamblett, N., Thibodeau, P. H., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00324-7 · Cited by 61 · see citing works

Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain

Kerem, E., Orenti, A., Adamoli, A., Hatziagorou, E., Naehrlich, L., & Sermet‐Gaudelus, I. (2024) · European Respiratory Journal · doi:10.1183/13993003.01241-2023 · Cited by 44 · see citing works

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy

Jain, R., Peng, G., Lee, M., Keller, A. E., Cosmich, S., Reddy, S., West, N. E., Kazmerski, T. M., Goralski, J. L., Flume, P. A., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.09.019 · Cited by 33 · see citing works

New drugs, new challenges in cystic fibrosis care

Fajac, I., Burgel, P., & Martin, C. (2024) · European Respiratory Review · doi:10.1183/16000617.0045-2024 · Cited by 25 · see citing works

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

Tümmler, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158207 · Cited by 22 · see citing works

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population

Somerville, L., Borish, L., Imre, N., & Albon, D. P. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241297877 · Cited by 21 · see citing works

Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment

Wu, M., Davis, J. D., Zhao, C., Daley, T. C., & Oliver, K. E. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100344 · Cited by 19 · see citing works

Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study

Connett, G. J., Maguire, S., Larcombe, T., Scanlan, N., Shinde, S. S., Muthukumarana, T., Bevan, A., Keogh, R. H., & Legg, J. P. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107882 · Cited by 15 · see citing works

Real world study on elexacaftor‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis

Lonabaugh, K. P., Li, G., List, R., Huang, R., James, A., Barros, A. J., Somerville, L., & Albon, D. P. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2903 · Cited by 14 · see citing works

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Vega-Hernandez, G., MacGregor, G., Wilfin, A., Adams, F., Haugh, C., Baxter, C. A., Wöhling, H., Clarke, S. L., Charman, S. C., & Carr, S. B. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.04.012 · Cited by 13 · see citing works

Trials and tribulations of highly effective modulator therapies in cystic fibrosis

Lieu, N., Prentice, B. J., Field, P., & Fitzgerald, D. A. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.09.001 · Cited by 13 · see citing works

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

Schütz, K., Pallenberg, S. T., Kontsendorn, J., DeLuca, D. S., Sukdolak, C., Minso, R., Büttner, T., Wetzke, M., Dopfer, C., Sauer‐Heilborn, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171544 · Cited by 12 · see citing works

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis

Xu, W., Wu, T., Zhou, Z., & Zuo, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1275470 · Cited by 11 · see citing works

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

Harris, W. T., Baker, E. H., Guimbellot, J. S., Collaco, J. M., Schechter, M. S., & Oates, G. R. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.05.002 · Cited by 8 · see citing works

Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort

Leo‐Hansen, C., Faurholt‐Jepsen, D., Qvist, T., Højte, C., Nielsen, B. U., Bryrup, T., Henriksen, E. H., Katzenstein, T. L., Skov, M., Mathiesen, I. H. M., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00339-2024 · Cited by 8 · see citing works

Effects of CFTR Modulators on Pseudomonas aeruginosa Infections in Cystic Fibrosis

Pescaru, C. C., Crișan, A. F., Marițescu, A., Cărunta, V., Marc, M. S., Dumitrache‐Rujinski, S., Laitin, S. M. D., & Oancea, C. I. (2025) · Infectious Disease Reports · doi:10.3390/idr17040080 · Cited by 7 · see citing works

CFTR Modulators Therapy Efficacy in Reducing Cystic Fibrosis (CF) Exacerbation and Improving Selected Spirometry Parameters: A Real-Life Study in a Single-Centre Polish Population

Winiarska, H. M., Springer, D., Wojtaś, F., Wysocka, E., & Cofta, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154491 · Cited by 6 · see citing works

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Merlo, C. A., Thorat, T., McGarry, L. J., Scirica, C. V., DerSarkissian, M., Nguyen, C., Gu, Y. M., Muthukumar, A., Healy, J., Rubin, J. L., et al. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00269-9 · Cited by 6 · see citing works

Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis

Sheikh, S. I., Holtzlander, M., Eisner, M., Gushue, C. A., PALACIOS, S. K., Kotha, K. S., Imran, S., & McCoy, K. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102345 · Cited by 6 · see citing works

Cystic fibrosis year in review 2022

Kim, J., Lyman, B. C., & Savant, A. P. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26641 · Cited by 6 · see citing works

Real -world impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor

Holtzlander, M., Lind, M., Eisner, M., Gushue, C. A., PALACIOS, S. K., Kotha, K. S., Imran, S., McCoy, K., & Sheikh, S. I. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108274 · Cited by 5 · see citing works

Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials

Mayer-Hamblett, N., Kerper, N. R., Clancy, J. P., Davies, J. C., Taylor‐Cousar, J. L., Donaldson, S. H., Bell, S. C., Jain, R., Simmonds, N. J., Mall, M. A., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00206-1 · Cited by 4 · see citing works

Falling through the Cracks—The Impact of Care Gaps on Lung Function Loss in Cystic Fibrosis

Love, A. J., & Quon, B. S. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202305-459ed · Cited by 4 · see citing works

Effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry

Alicandro, G., Terlizzi, V., Zazzeron, L., Dolce, D., Cariani, L., Fiandaca, A., Campana, S., Terminiello, A., Innocenti, D., Blasi, F., et al. (2025) · Pediatric Research · doi:10.1038/s41390-025-04552-6 · Cited by 3 · see citing works

Qualitative Analysis of Perspectives on Lung Transplant among People with Cystic Fibrosis

Milinic, T., Hobler, M. R., Bartlett, L., Gill, E. R., Burdis, N., Engelberg, R. A., Curtis, J. R., Hartzler, A. L., Aitken, M. L., Kapnadak, S. G., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202307-625oc · Cited by 3 · see citing works

Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis

Konstan, M. W., Polineni, D., Chmiel, J. F., Bilodeau, L., Middleton, P. G., Matouk, E., Houle, J., Pislariu, R., Colin, P., Kianicka, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.07.004 · Cited by 3 · see citing works

Nanoparticles as Drug Delivery Vehicles for People with Cystic Fibrosis

Hourihane, E., & Hixon, K. R. (2024) · Biomimetics · doi:10.3390/biomimetics9090574 · Cited by 3 · see citing works

Cystic fibrosis year in review 2023

Swetland, D. V., & Savant, A. P. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27190 · Cited by 3 · see citing works

Outcomes of Modulator Therapy Discontinued After Short‐Term Use in Adult Cystic Fibrosis

Karcıoğlu, O., İdikut, A., Öztürk, E., & Damadoğlu, E. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27416 · Cited by 2 · see citing works

Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US

Burdis, N., Bradford, M. C., Heltshe, S. L., Milinic, T., McElvaney, O. J., Lease, E. D., Goss, C. H., Kapnadak, S. G., Guthrie, B. L., & Ramos, K. J. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.06.005 · Cited by 2 · see citing works

The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution

Semenchuk, J. A., Tuff-Gordon, E., Ma, X., Sykes, J. R., Cheng, S. Y., Aversa, M. M., Chaparro, C., Tullis, E. D., & Stephenson, A. L. (2025) · Clinical Transplantation · doi:10.1111/ctr.70317 · Cited by 2 · see citing works

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation

Edwards, S. J., Farrar, B. G., Ennis, K., Downes, N., Wakefield, V., Mackenzie, I., Walters, A., & Jhita, T. (2024) · Health Technology Assessment · doi:10.3310/cpld8546 · Cited by 2 · see citing works

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

CADTH (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.826 · Cited by 2 · see citing works

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations

McKinnon, C. J., Thorat, T., Craft, A., & Higgins, M. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002033 · Cited by 2 · see citing works

Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry

Orenti, A., Boeck, K. D., Kerem, E., Burgel, P., Zolin, A., Bakkeheim, E., Naehrlich, L., Hatziagorou, E., Aleksejeva, E., Appelt, D., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00149-9 · Cited by 1 · see citing works

Reliability of Clinic-Obtained vs Self-Obtained Respiratory Samples From the Self-Sample Accuracy and Benefit Implementation Trial (S2wAB-IT)

Hoppe, J. E., Paisley, A., Vigers, T., Moffett, K. S., Indihar, V., Dasenbrook, E. C., Mortensen, J. E., Muhlebach, M. S., & Siracusa, C. M. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.12.036 · Cited by 1 · see citing works

614 Time between clinic visits of individuals with cystic fibrosis: patterns across the lifespan

Hinton, A., Sears, E. H., López‐Pintado, S., & Zuckerman, J. B. (2023) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(23)01536-9 · Cited by 1 · see citing works

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Zhou, G. C., Wang, Z., Palipana, A., Andrinopoulou, E., Afonso, P. M., McPhail, G. L., Siracusa, C. M., Gecili, E., & Szczesniak, R. D. (2024) · Respiratory Research · doi:10.1186/s12931-024-02794-2 · Cited by 1 · see citing works

Regarding the article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis”

Hoo, Z. H., Lai, L. Y. H., Sandler, R. D., Daniels, T. E., Dawson, S., Hutchings, M., & Wildman, M. J. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.03.012

613 Exploring FEV1 response by co-adherence to inhaled therapies in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor: year 1 of the NEEMO-CFHealthHub learning health system evaluation

Daniels, T., Lai, L. Y. H., Wildman, M. J., & Hoo, Z. H. (2023) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(23)01535-7

Improving (inhaled) antibiotic therapy in Cystic Fibrosis

Akkerman‐Nijland, A. M. (2024) · doi:10.33612/diss.950093041

Secular and modulator-specific drifts in the predictive performance of a rapid lung function decline algorithm: a cystic fibrosis patient registry study

Wang, Z., Zhou, G. C., Palipana, A., Gecili, E., Dexheimer, J. W., Siracusa, C. M., & Szczesniak, R. D. (2024) · Discover Data · doi:10.1007/s44248-024-00014-2

Tolerability of inhaled mannitol in children with cystic fibrosis: initiation dose assessment

Goryainova, A., Semykin, S. Y., Kazarova, L. S., & Kashirskaya, N. Y. (2025) · PULMONOLOGIYA · doi:10.18093/0869-0189-2025-35-3-332-339

Evolving cystic fibrosis care models in the modulator era

Martin, I., Ratjen, F. A., & Flume, P. A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001215

Additional file 1 of Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Zhou, G. C., Wang, Z., Palipana, A., Andrinopoulou, E.-R., Afonso, P. M., McPhail, G. L., Siracusa, C. M., Gecili, E., & Szczesniak, R. D. (2024) · Figshare · doi:10.6084/m9.figshare.26713634

Comparison of Single‐Breath and Multi‐Breath Xe‐ MRI in the Longitudinal Assessment of Treatment in Children With Cystic Fibrosis

Alam, F. S., Munidasa, S. R., Zanette, B., Li, D., Braganza, S., Ratjen, F. A., & Santyr, G. E. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70242

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis in the United States

Hergenroeder, G. E., Todd, J., Ostrenga, J. S., Goss, C. H., Jain, R., Morgan, W., Sawicki, G. S., Schechter, M. S., Szczesniak, R. D., Cromwell, E. A., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag095

Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19

Merlo, C., Romdhani, H., DerSarkissian, M., Muthukumar, A., McGarry, L. J., Lou, Y., & Brunt, K. V. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00363-0

Clinical characteristics and outcomes of people with cystic fibrosis with homozygous minimal function genotypes compared to those with F508del/minimal function genotypes

Konstan, M. W., Lumsden, B., Menon, P. R., DerSarkissian, M., & Rice, M. S. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109079

Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania

Marinău, C., Sava, C. N., Iuhas, A., Ciucă, I. M., Pop, L. L., Niulaș, L., Szilágyi, A., Jurca, A., & Jurca, C. M. (2026) · Children · doi:10.3390/children13091178

Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis

Doumat, G., Iyer, M., & Jain, R. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001314

Respiratory health in cystic fibrosis: much done, more to do!

Weinberg, S. E., & Barry, P. J. (2026) · Thorax · doi:10.1136/thorax-2026-225819

Regarding the article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis”

Hoo, Z. H., Lai, L. Y. H., Sandler, R. D., Daniels, T. E., Dawson, S., Hutchings, M., & Wildman, M. J. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.03.012

Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease

Savi, D., Lucca, F., Tridello, G., Meneghelli, I., Comello, I., Tomezzoli, S., Signorini, M., Proietti, E., Cucchetto, G., Volpi, S., et al. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107406 · Cited by 12 · see citing works

A One-Year Retrospective Analysis of the Effect of Elexacaftor-Tezacaftor-Ivacaftor on Lung Function in Cystic Fibrosis Patients with Advanced Lung Disease

Bermingham, B., Rueschhoff, A., Ratti, G. A., NeSmith, A., Flume, P. A., Solomon, G. M., Cohen, L., & Garcia, B. A. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2026 · Cited by 1 · see citing works

Efficacy of elexacaftor/tezacaftor/ivacaftor in decreasing severe cystic fibrosis-related exacerbations: a retrospective, within-group studyPreprint

Rhudy, C. N., Kormelink, L. N., Taylor, B., Hegnauer, S., Autry, E. B., Zeltner, M., & Platt, T. (2024) · doi:10.22541/au.170669896.68728792/v1

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Merlo, C. A., Thorat, T., McGarry, L. J., Scirica, C. V., DerSarkissian, M., Nguyen, C., Gu, Y. M., Muthukumar, A., Healy, J., Rubin, J. L., et al. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00269-9 · Cited by 6 · see citing works